Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.

Background/Objectives: Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need. To address this gap, we developed the SUVmax-IPI, a novel prognostic index combining maximum standardized uptake value (SUVmax) from ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) with systemic inflammatory markers. This study aimed to evaluate the prognostic value of SUVmax-IPI in patients with NSCLC receiving nivolumab therapy. Methods: This multicenter retrospective analysis included 187 patients with metastatic NSCLC receiving nivolumab across 5 tertiary institutions. The SUVmax-IPI incorporated pretreatment SUVmax and laboratory-based inflammatory prognostic index (IPI) parameters. Survival outcomes were evaluated using Kaplan–Meier analysis with log-rank testing and multivariate cox regression. Results: Receiver operating characteristic (ROC) analysis established an optimal SUVmax-IPI cut-off of 241.9. Patients with SUVmax-IPI ≤ 241.9 had significantly better survival outcomes: median overall survival (OS) was 35 versus 15 months (p = 0.002). For progression-free survival (PFS), although a numerical difference favored patients with SUVmax-IPI ≤ 241.9 (median: 15 vs. 8 months), this did not reach statistical significance (log-rank p = 0.175). Multivariate analysis confirmed SUVmax-IPI as an independent predictor of survival (p = 0.002). Conclusions: The SUVmax-IPI represents a promising prognostic tool for patients with metastatic NSCLC who received at least 3 months of nivolumab, integrating metabolic and inflammatory parameters to predict survival outcomes.

Background/Objectives: Trastuzumab emtansine (T-DM1) is widely used in Human Epidermal Growth Factor Receptor2 (HER2)-positive metastatic breast cancer; however, outcomes vary, and reliable prognostic markers remain limited. We developed the CALA index as a composite biomarker integrating CA15-3, lactate dehydrogenase (LDH), and albumin. This study aimed to evaluate the prognostic value of the CALA index in metastatic breast cancer treated with T-DM1. Methods: This multicenter retrospective study included 168 patients treated with T-DM1 across four tertiary centers. The CALA index was calculated using pretreatment levels of CA15-3, LDH, and albumin. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value, and patients were stratified into groups accordingly. Survival outcomes and independent risk factors were assessed using Kaplan–Meier and Cox regression analyses. Results: The median overall survival (OS) was 26 months (95% CI: 21.3–30.7). ROC analysis identified an optimal CALA cutoff value of 118.3. Patients with CALA ≤ 118.3 demonstrated significantly longer OS compared with those with CALA > 118.3 (log-rank p = 0.006), with 1- and 3-year OS rates of 81.2% and 43.2% versus 69.8% and 22.7%, respectively. In univariate analysis, CALA > 118.3 was associated with worse OS (HR: 1.699; 95% CI: 1.151–2.506; p = 0.008), and this association remained significant in multivariate analysis (HR: 1.671; 95% CI: 1.088–2.565; p = 0.019). Conclusions: The CALA index was associated with overall survival in metastatic breast cancer treated with trastuzumab emtansine and may serve as a practical tool for risk stratification.

Nöroendokrin tümörler başta akciğer ve gastrointestinal sistem olmak üzere tüm vücutta görülebilen nadir tümörlerdir.(1,2) Akciğer karsinomlarının %20 ‘sini oluşturur.(1,2) Akciğer nöroendokrin tümörlerde vena kava süperior sendromu (VKSS) sıklığı bilinmemektedir. İntratorasik maligniteler VKSS’nin %60-%85’inden sorumludur ve tümör tanısı önceden konulmamış bu olguların %60 ‘ı vena kava superior obstrüksiyonu ile prezente olur. Bu olgularda venöz obstrüksiyon; vena kava süperiora primer tümörün, mediastinal lenf nodlarının dıştan basısı veya direk tümör invazyonu sonucunda meydana gelir. Literatürde sağkalım verileri olgu sunumu düzeyinde olmakla birlikte tedavisiz kalan olgularda sağkalım 1 ay civarında bildirilmektedir. Bu nedenle hızlı tanı konulup uygun tedavinin planlanması hayati önem taşımaktadır. Burada akciğer nöroendokrin tümör nedeniyle VKSS gelişen olgunun tanısal süreci ve prognozu sunulmuştur.

Objective: This study aimed to assess the prognostic significance of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer (NSCLC) receiving nivolumab as second-line therapy. The study also explored associations between these parameters, treatment response, and survival outcomes. Methods: A retrospective analysis was performed on 32 stage IV NSCLC patients who received at least four doses of nivolumab and underwent both baseline and follow-up PET/CT scans. Metabolic parameters, including SUVmax, SUVmean, total metabolic tumor volume (tMTV), and total lesion glycolysis (tTLG), were measured. Treatment response was classified according to EORTC criteria. Kaplan–Meier analysis and log-rank tests were applied for survival comparisons, and non-parametric methods evaluate associations. Results: Patients with partial metabolic response demonstrated significantly longer post-nivolumab survival. Post-treatment SUVmax, SUVmean, and tTLG differed significantly among response categories. Pretreatment tMTV and tTLG, and post-treatment SUVmax, SUVmean, and tTLG, were significantly associated with mortality (p

Round pnömoni çocuklarda daha sık, yetişkinlerde ise nadir görülen bir akciğer enfeksiyonudur. Akciğer grafilerinde oval şekilli lezyonlar olarak görülmesinden dolayı bronkojenik karsinom ile karıştırılabilmektedir. Genellikle benign seyir göstermesi ve antibiyoterapiyle rezolüsyona uğraması pulmoner malignitelerden ayırt edilmesini sağlar. Biz burada, round pnömoni saptadığımız ve antibiyotik tedavisi sonrasında klinik ve radyolojik düzelme sağlanan bir olguyu sunduk. Klinisyenler akciğer malignitelerini görünüm olarak taklit edebilen, nadir görülen bu pnömoni tipini gereksiz tanısal testlerden kaçınmak için akılda bulundurmalıdır.